Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have received an average rating of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.6667.

ACRV has been the subject of a number of research reports. Wall Street Zen downgraded Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st. Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Finally, Weiss Ratings upgraded Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday.

Hedge Funds Weigh In On Acrivon Therapeutics

Large investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC bought a new position in Acrivon Therapeutics in the fourth quarter worth about $40,000. Vermillion & White Wealth Management Group LLC bought a new position in Acrivon Therapeutics in the fourth quarter worth about $44,000. Focus Partners Wealth bought a new position in Acrivon Therapeutics in the third quarter worth about $36,000. Quadrature Capital Ltd bought a new position in Acrivon Therapeutics in the fourth quarter worth about $50,000. Finally, Invesco Ltd. bought a new position in Acrivon Therapeutics in the first quarter worth about $72,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

NASDAQ:ACRV opened at $1.51 on Thursday. The company has a market capitalization of $64.63 million, a price-to-earnings ratio of -0.76 and a beta of 1.89. Acrivon Therapeutics has a one year low of $1.15 and a one year high of $3.56. The stock has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $1.90.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). On average, equities research analysts forecast that Acrivon Therapeutics will post -1.92 EPS for the current fiscal year.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.